Renal cell carcinoma and the use of sorafenib.
作者： Tim Eisen , James Mg Larkin
DOI:
关键词: Phases of clinical research 、 Renal cell carcinoma 、 Vascular endothelial growth factor 、 Angiogenesis 、 Receptor tyrosine kinase 、 Cancer research 、 Pathology 、 Medicine 、 Sorafenib 、 Platelet-derived growth factor receptor 、 Immunotherapy
摘要: Immunotherapy results in a small overall survival advantage metastatic renal cell carcinoma (RCC), but there is need to develop more effective systemic therapies. Angiogenesis has an important role the pathophysiology of RCC and vascular endothelial growth factor (VEGF) key mediator this process. Sorafenib (BAY 43-9006) new agent belonging class drugs called kinase inhibitors inhibits VEGF, platelet-derived (PDGF), c-KIT receptor tyrosine kinases, amongst others. shown significant activity with manageable toxicity phase 2 studies patients pretreated immunotherapy, whilst prolonged progression-free comparison placebo 3 study been reported. Further trials advanced disease are ongoing trial adjuvant sorafenib therapy planned.
参考文章(101)
Martin E Gleave, Mostafa Elhilali, Yves Fradet, Ian Davis, Peter Venner, Fred Saad, Laurence H Klotz, Malcolm J Moore, Virginia Paton, Alex Bajamonde, David Bell, Scott Ernst, Ernest Ramsey, Joe Chin, Alvaro Morales, Heidi Martins, Coree Sanders, Canadian Urologic Oncology Group, None, Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell Carcinoma The New England Journal of Medicine. ,vol. 338, pp. 1265- 1271 ,(1998) , 10.1056/NEJM199804303381804
Matthias H. Kraus, Yoshitaka Ebi, Hitoshi Onoue, Yukihiko Kitamura, Shiv K. Srivastava, Johng S. Rhim, Jun Fujita, Activated H-ras Oncogenes in Human Kidney Tumors Cancer Research. ,vol. 48, pp. 5251- 5255 ,(1988)
Napoleone Ferrara, Kenneth J Hillan, Hans-Peter Gerber, William Novotny, None, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nature Reviews Drug Discovery. ,vol. 3, pp. 391- 400 ,(2004) , 10.1038/NRD1381
E Yildiz, GÖKHAN Gokce, H Kilicarslan, S Ayan, OF Goze, EY Gultekin, Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma. BJUI. ,vol. 93, pp. 1087- 1093 ,(2004) , 10.1111/J.1464-410X.2004.04786.X
Chris Coppin, Franz Porzsolt, Michael Autenrieth, Julia Kumpf, Andrew Coldman, Timothy Wilt, Immunotherapy for advanced renal cell cancer Cochrane Database of Systematic Reviews. ,vol. 2015, ,(2015) , 10.1002/14651858.CD001425.PUB2
Lei Xu, Ricky Tong, David M. Cochran, Rakesh K. Jain, Matrix metalloproteinase-2 contributes to cancer cell migration on collagen. Cancer Research. ,vol. 65, pp. 130- 136 ,(2005) , 10.1158/0008-5472.CAN-04-4313
Giorgio Pizzocaro, Luigi Piva, Maria Colavita, Sonia Ferri, Raffaella Artusi, Patrizia Boracchi, Giorgio Parmiani, Ettore Marubini, Interferon Adjuvant to Radical Nephrectomy in Robson Stages II and III Renal Cell Carcinoma: A Multicentric Randomized Study Journal of Clinical Oncology. ,vol. 19, pp. 425- 431 ,(2001) , 10.1200/JCO.2001.19.2.425
David T. Harris, Hormonal therapy and chemotherapy of renal-cell carcinoma. Seminars in Oncology. ,vol. 10, pp. 422- 430 ,(1983) , 10.5555/URI:PII:0093775483900520
Osamu Yoshida, Yuji Chatani, Toshiro Terachi, Yoshiyuki Kakehi, Rika Hoshino, Yusaku Okada, Osamu Ogawa, Hiroya Oka, Masashi Kawaichi, Michiaki Kohno, Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Research. ,vol. 55, pp. 4182- 4187 ,(1995)
Seppo Pyrhönen, Eeva Salminen, Mirja Ruutu, Timo Lehtonen, Martti Nurmi, Teuvo Tammela, Harri Juusela, Erkki Rintala, Päivi Hietanen, Pirko-Liisa Kellokumpu-Lehtinen, Prospective Randomized Trial of Interferon Alfa-2a Plus Vinblastine Versus Vinblastine Alone in Patients With Advanced Renal Cell Cancer Journal of Clinical Oncology. ,vol. 17, pp. 2859- 2859 ,(1999) , 10.1200/JCO.1999.17.9.2859